Unlock instant, AI-driven research and patent intelligence for your innovation.

Biased agonists and their medicinal uses

A pharmacy, compound technology, applied in the field of biased agonists and their medicinal uses

Active Publication Date: 2022-06-03
ACADEMY OF MILITARY MEDICAL SCI
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the analgesic activity of PZM21 needs to be further improved

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biased agonists and their medicinal uses
  • Biased agonists and their medicinal uses
  • Biased agonists and their medicinal uses

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0207] Example 1: 1-((S)-3-(benzo[d][1,3]dioxol-4-yl)-2-(dimethylamino)propyl)-3- Synthesis of ((S)-1-(thiophen-3-yl)propan-2-yl)urea (Ia-1)

[0208]

[0209] 1.1(S)-2-Amino-3-(benzo[d][1,3]dioxol-4-yl)propanamide (2a) and (S)-2-amino-3-( Synthesis of Benzo[d][1,3]dioxol-5-yl)propionamide (2b)

[0210]

[0211] Weigh 10.00g (40.70mmol) of L-benzo[d][1,3]dioxol-4-ylalanine (1a) or L-benzo[d][1,3]diol Oxol-5-ylalanine (1b) was placed in a 250 mL two-necked flask, and 150 mL of methanol was added, which could not be dissolved, and was a milky white suspension. Under ice bath and stirring, 14.50g (122.00mmol) thionyl chloride was slowly added dropwise, the exotherm was violent, the temperature was controlled below 10°C, the solution was gradually clarified, and after the addition of materials, the reaction was naturally raised to room temperature for 12h, and the reaction was complete after TLC detection. Stop the reaction. The reaction solution was transferred to a 250 ...

Embodiment 2

[0231] Example 2 1-((S)-3-(benzo[d][1,3]dioxol-4-yl)-2-(dimethylamino)propyl)-3-( Synthesis of 2-(thiophen-3-yl)ethyl)urea (Ia-2)

[0232]

[0233] 2.1 Synthesis of 4-nitrophenyl 2-(thiophen-3-yl)ethylcarbamate (6a-2)

[0234]

[0235] Weigh 3.55g (27.94mmol) of 3-ethylaminothiophene (5a-2) into a 500mL three-necked flask, add 50mL of ultra-dry THF in an ice bath, stir, and under argon protection, dropwise add 8.00mL (55.88mmol) of triethyl For the amine, 6.20 g (30.74 mmol) of phenyl p-nitrochloroformate was weighed, dissolved in 30 mL of ultra-dry THF, and added dropwise to the reaction solution. After the addition of materials, the temperature was naturally raised to room temperature, and the reaction was completed by TLC for 6 h, and the reaction was stopped. Add 100 mL of dichloromethane to dilute the reaction solution, filter with suction, and filter the filtrate through saturated NaHCO. 3 The solution (200 mL×3) and saturated brine (200 mL) were washed. The or...

Embodiment 3

[0239] Example 3 1-((S)-3-(benzo[d][1,3]dioxol-5-yl)-2-(dimethylamino)propyl)-3-( Synthesis of (S)-1-(thiophen-3-yl)propan-2-yl)urea (Ia-3)

[0240]

[0241] Weigh 0.46g (1.56mmol) of 4b and place it in a 50mL three-necked flask, add 15mL of acetonitrile under argon protection, add 0.70mL (4.69mmol) of triethylamine dropwise, heat up to 60°C, weigh 0.48g (1.56mmol) of 6a -1 was dissolved in 10 mL of acetonitrile and added dropwise to the reaction solution. The reaction solution turned from colorless to yellow. After the addition of materials, the temperature was raised to 80 °C and stirred for 8 h. The reaction was complete after TLC detection. The reaction was stopped, suction filtered, the filtrate was evaporated to dryness under reduced pressure, and the residue was dissolved in 30 mL of EA / isopropanol (2:1) mixed solvent. The solution was pH= 9 NaCO 3 / NaHCO 3 Buffer wash 20mL×3. The organic phase was dried over anhydrous sodium sulfate, concentrated under reduced p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to compounds represented by structural formulas I and II, their stereoisomers or pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing these compounds, their stereoisomers or their pharmaceutically acceptable salts as active ingredients , and the use of the compound, its stereoisomer or a pharmaceutically acceptable salt thereof for the preparation of an analgesic drug,

Description

technical field [0001] The present invention relates to novel μ-opioid receptor-biased agonists, stereoisomers thereof or pharmaceutically acceptable salts thereof, and medicaments containing these compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof as active ingredients Compositions, and use of the compounds, stereoisomers or pharmaceutically acceptable salts thereof for the manufacture of analgesic medicaments. Background technique [0002] Opioid potent analgesics are still the most effective pain relievers at present, but their addiction, respiratory depression and other serious side effects are also the biggest challenges facing these drugs. For a long time, the treatment of moderate to severe pain has also relied on opioids. [0003] In recent years, studies have found that the ligands of some GPCRs show an "unbalanced effect" when activating signaling pathways, they can bind to specific receptor forms, or can induce receptors to selectively ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D409/12C07D495/04C07D317/58A61K31/381A61K31/4365A61K31/36A61P25/04
CPCC07D409/12C07D495/04C07D317/58A61P25/04Y02P20/55
Inventor 史卫国李翔马梦君任凤霞童坤于子兴程京超仲伯华
Owner ACADEMY OF MILITARY MEDICAL SCI